Financial Summary (Q2 2026)
Koninklijke Philips reported total group sales of EUR 4,360 million for Q2 2026, delivering 4% comparable sales growth year-over-year. Reported net income benefited significantly from a one-time USD 211 million (EUR ~190 million) U.S. tariff refund. Adjusted EBITA reached EUR 717 million, bringing the reported margin to 16.4% (+400 bps YoY).Excluding the tariff benefit, the underlying EBITA margin stood at 12.2% (-20 bps YoY), as price adjustments and EUR 132 million in quarterly productivity savings were offset by operational cost inflation and currency pressure.Free cash flow for the quarter was EUR 222 million.
Revenue Breakdown by Segment and Region
Segment Breakdown
- Diagnosis & Treatment (48% of Total Sales):EUR 2,093 million (4% comparable sales growth). This division develops diagnostic imaging (MRI, CT, Ultrasound) and image-guided therapy systems. Growth was driven by strength in Ultrasound and Image-Guided Therapy, offset by supply constraints and macroeconomic softness in China.
- Connected Care (31% of Total Sales): EUR 1,352 million (4% comparable sales growth). This business provides hospital patient monitoring systems, enterprise healthcare informatics, and sleep/respiratory care devices. Patient Monitoring led growth in North America and Europe, while Enterprise Informatics experienced minor declines.
- Personal Health (21% of Total Sales):EUR 915 million (4% comparable sales growth). This consumer-facing segment sells personal care, oral healthcare (Sonicare), and mother/child care products. Growth was led by strong demand in Europe and North America, expanding margins to 23.0% reported (18.0% underlying).
Regional Performance
- North America (~40% of Total Sales): Showed resilient mid-single-digit demand, driven by strong hospital spending on capital equipment and patient monitoring platforms.
- Mature Geographies (Europe / Other): Europe recorded solid mid-to-high single-digit growth across all three product divisions.
- Growth Geographies (Including China): Remained under pressure due to delayed hospital tender activities and regulatory anti-corruption initiatives affecting procurement cycles in China.
Operational Changes, Next Quarter Focus, and Outlook
Recent Operational Changes
- Delivered EUR 132 million in structural cost savings during Q2 2026 through Project Synchronize (part of a broader EUR 1.5 billion cost-cutting initiative through 2028).
- De-leveraged the balance sheet, reducing the net debt-to-adjusted EBITDA ratio from 2.2x to 1.8x.
Next Quarter Focus & Future Outlook
- Key Focus Areas: Execution of supply chain cost optimization, stabilization of order books in mainland China, and final resolutions regarding lingering legal liabilities for Respironics.
- Full-Year 2026 Outlook:Management expects full-year comparable sales growth of 3.0% to 4.5%. Supported by the U.S. tariff windfall, the target for adjusted EBITA margin was nudged higher to 12.5%–13.0%, with projected full-year free cash flow expected between EUR 1.3 billion and EUR 1.5 billion.
Stock Price Performance (Past 3 Months)
Over the past three months (May to August 2026), Philips’ NYSE-listed shares (PHG) fluctuated between $23.85 and $28.50, trading near $26.95 by late August.
- May 2026:Shares rallied over 5% following a strong Q1 report that beat market expectations on operational growth and order intake.
- July 2026: Following the Q2 earnings release on July 28, the stock experienced a ~4.4% pull-back despite a headline EPS beat. Investors reacted cautiously after digesting that the earnings outperformance was heavily driven by the $211M tariff refund rather than core margin expansion, along with ongoing concerns over legal litigation overhangs.
- August 2026: Shares stabilized in a tight range near $26.90 to $27.00 as market consensus settled on a “Hold” stance pending clearer visibility into organic growth metrics for H2 2026.
Information Sources
- https://www.results.philips.com/
- https://quartr.com/events/koninklijke-philips-n-v-phia-q2-2026_33NTKQdx
- https://247wallst.com/cards/koninklijke-philips-q2-2026-earnings-phg-01kym3mxqf47xex1g2p8ejf72d
- https://www.investing.com/news/company-news/philips-q2-2026-slides-growth-across-segments-but-margins-face-pressure-93CH-4815637
- https://www.marketbeat.com/instant-alerts/consensus-koninklijke-philips-nv-nyse-phg-receives-average-recommendation-of-hold-from-analysts-2026-08-28/
Back to Philips